Sarcoidosis of the lung is a condition where tiny clusters of inflammatory cells, called granulomas, form in lung tissue and nearby lymph nodes. It affects roughly 230 per 100,000 people and is the most common form of sarcoidosis, a disease that can appear in almost any organ. Most people with pulmonary sarcoidosis recover fully, many without ever needing treatment, but a small percentage develop lasting lung damage.
What Happens Inside the Lungs
Sarcoidosis begins when the immune system overreacts to something it perceives as a threat, though the exact trigger remains unknown in most cases. Immune cells called macrophages swallow the offending substance and, rather than clearing it, begin clustering together. These clusters recruit more immune cells, including certain white blood cells and cells that build connective tissue, eventually forming a tiny ball of inflammation: the granuloma.
Granulomas act as walls, sealing off whatever triggered the immune response to protect surrounding tissue. In pulmonary sarcoidosis, they tend to form along the airways, around blood vessels, and in the thin tissue between the lung’s air sacs. They also commonly appear in the lymph nodes near the center of the chest. When enough granulomas accumulate, they can stiffen the lung tissue and interfere with the normal exchange of oxygen and carbon dioxide, which is what causes breathing symptoms.
Common Symptoms
Many people with lung sarcoidosis have no symptoms at all. The disease is frequently discovered by accident on a chest X-ray taken for another reason. When symptoms do appear, they typically include a persistent dry cough, shortness of breath (especially with exertion), wheezing, and chest pain or tightness.
Sarcoidosis also causes whole-body symptoms that can be harder to connect to a lung problem. Fatigue is one of the most common and most disabling complaints, often persisting even after the lung inflammation improves. Other systemic symptoms include unexplained weight loss, low-grade fever, heavy night sweats, swollen lymph nodes, and depression. Because these overlap with many other conditions, diagnosis can take time.
Löfgren’s Syndrome
A distinctive variant called Löfgren’s syndrome involves a triad of swollen lymph nodes in the chest, painful red bumps on the shins (erythema nodosum), and sudden joint pain, particularly in the ankles. It tends to come on abruptly and looks alarming, but it actually carries one of the best prognoses of any form of sarcoidosis. It typically resolves on its own with nothing more than anti-inflammatory pain relievers.
Who Is Most Affected
Pulmonary sarcoidosis most often appears between ages 25 and 40, with a smaller second peak in women over 50. It occurs across all ethnicities and geographies, but rates are notably higher in people of African and Scandinavian descent. In these groups, the disease also tends to be more severe and more likely to become chronic. Women are slightly more likely to develop it than men.
How It Is Diagnosed
A chest X-ray is usually the first clue. Doctors classify what they see on the X-ray into stages, which helps predict how the disease will behave:
- Stage I: Enlarged lymph nodes in the center of the chest, but the lungs themselves look clear.
- Stage II: Enlarged lymph nodes plus visible changes in the lung tissue.
- Stage III: Lung tissue changes without enlarged lymph nodes.
- Stage IV: Permanent scarring (fibrosis) visible in the lungs.
A chest X-ray alone is not enough to confirm the diagnosis. Because granulomas can be caused by infections like tuberculosis or by certain cancers, doctors typically need a tissue sample. The most common way to get one is through a bronchoscopy, where a thin, flexible camera is guided into the airways. A technique called endobronchial ultrasound-guided needle aspiration allows doctors to sample the swollen lymph nodes directly through the airway wall. A meta-analysis of 553 patients found this approach correctly identifies sarcoidosis about 79% of the time, with some studies reporting yields above 90%. Breathing tests (spirometry) and CT scans round out the evaluation by measuring how well the lungs function and revealing the extent of granuloma involvement.
Outlook by Stage
The stage at diagnosis is one of the strongest predictors of what comes next. Stage I disease resolves on its own in 60 to 90% of cases, often within one to two years. Stage II resolves spontaneously in roughly 40 to 70% of patients. Stage III has a much lower spontaneous remission rate, around 10 to 20%. Stage IV, where permanent scarring has already formed, does not reverse.
Overall, functional impairment from sarcoidosis occurs in only about 15 to 20% of patients and often improves without intervention. However, the disease does progress in more than 10% of cases, and progression to chronic or fibrotic disease carries a mortality rate of 12 to 18% within five years. About 5% of all sarcoidosis patients develop significant pulmonary fibrosis, where scar tissue permanently replaces healthy lung tissue and reduces breathing capacity.
Treatment
Because so many cases resolve on their own, the first step for people with mild or no symptoms is often careful monitoring rather than immediate medication. Doctors typically recheck imaging and lung function every few months to see whether the disease is stable, improving, or worsening.
When treatment is needed, corticosteroids are the standard first-line therapy. A typical course starts at a moderate dose and is gradually tapered over about six months. Earlier guidelines called for higher starting doses, but current practice favors lower initial doses that are still effective and cause fewer side effects. Even short courses lasting a few weeks can bring lung function back to baseline during flare-ups.
For people with stage II disease, early treatment with oral corticosteroids followed by an inhaled steroid for over a year has been shown to improve lung function at the five-year mark and reduce the need for additional steroid courses down the road. For patients who relapse when steroids are tapered, or who cannot tolerate the side effects, doctors can add steroid-sparing medications that calm the immune system through different pathways.
In the small number of cases that progress to advanced fibrosis or pulmonary hypertension (high blood pressure in the lung’s blood vessels), treatment focuses on managing complications and preserving remaining lung function. Lung transplantation is an option for the most severe cases that no longer respond to medication.
Living With Pulmonary Sarcoidosis
Even when granulomas resolve and imaging looks normal, fatigue and reduced exercise tolerance can linger for months or years. This residual fatigue is one of the most frustrating aspects of the disease and is not always proportional to how much inflammation remains. Pulmonary rehabilitation, which combines structured exercise with breathing techniques, can help rebuild stamina.
People with sarcoidosis should be aware that the disease can involve other organs simultaneously or over time, including the skin, eyes, liver, and heart. Eye involvement in particular can be silent in its early stages, so periodic eye exams are a standard part of follow-up even when the lungs are the primary concern. Staying connected with a care team familiar with sarcoidosis makes it easier to catch new organ involvement early and adjust the monitoring schedule as the disease evolves.